In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price target of $94.00. The company’s shares closed last Friday at $87.74.
Biegelsen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Abbott Labs, and Boston Scientific. According to TipRanks, Biegelsen has an average return of 12.5% and a 62.61% success rate on recommended stocks.
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $89.86.
See Insiders’ Hot Stocks on TipRanks >>
EW market cap is currently $52.76B and has a P/E ratio of 38.12.
Based on the recent corporate insider activity of 113 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Earlier this month, Daveen Chopra, the CVP, TMTT of EW sold 8,200.00 shares for a total of $711,254.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences (EW) Company Description:
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
Read More on EW:
- Bad News for Edwards Lifesciences Corp. Stock: This New Risk Has Been Added
- Edwards Lifesciences price target raised to $100 from $90 at Barclays
- Edwards Lifesciences price target raised to $86 from $64 at Deutsche Bank
- Edwards Lifesciences price target raised to $95 from $82 at RBC Capital
- Edwards Lifesciences price target raised to $86 from $81 at Canaccord
